Endo Pharmaceuticals Looks For Acquisitions On Friday August 27, 2010, 4:40 pm EDT
To broaden its product base, Endo has also done some in-licensing. In July, 2009, Endo acquired exclusive rights from Bioniche Life Sciences to develop and market phase-three drug Urocidin for bladder cancer in the U.S. with a global marketing option.
Having bought Penwest, Endo can now make all the decisions about Opana without consultation.[B] It also won't need to pay Penwest the 22% in royalties[/B] that were part of the previous partnership deal.